DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
137.84
+1.72 (1.26%)
Jun 16, 2025, 4:00 PM - Market closed
DaVita Employees
DaVita had 76,000 employees as of December 31, 2024. The number of employees increased by 6,000 or 8.57% compared to the previous year.
Employees
76,000
Change (1Y)
6,000
Growth (1Y)
8.57%
Revenue / Employee
$170,638
Profits / Employee
$11,311
Market Cap
10.41B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76,000 | 6,000 | 8.57% |
Dec 31, 2023 | 70,000 | 0 | - |
Dec 31, 2022 | 70,000 | 1,000 | 1.45% |
Dec 31, 2021 | 69,000 | 2,000 | 2.99% |
Dec 31, 2020 | 67,000 | 2,000 | 3.08% |
Dec 31, 2019 | 65,000 | -12,700 | -16.34% |
Dec 31, 2018 | 77,700 | 3,200 | 4.30% |
Dec 31, 2017 | 74,500 | 4,200 | 5.97% |
Dec 31, 2016 | 70,300 | 9,900 | 16.39% |
Dec 31, 2015 | 60,400 | 2,500 | 4.32% |
Dec 31, 2014 | 57,900 | 500 | 0.87% |
Dec 31, 2013 | 57,400 | 4,000 | 7.49% |
Dec 31, 2012 | 53,400 | 12,400 | 30.24% |
Dec 31, 2011 | 41,000 | 4,500 | 12.33% |
Dec 31, 2010 | 36,500 | 2,500 | 7.35% |
Dec 31, 2009 | 34,000 | 1,500 | 4.62% |
Dec 31, 2008 | 32,500 | 1,500 | 4.84% |
Dec 31, 2007 | 31,000 | 2,100 | 7.27% |
Dec 31, 2006 | 28,900 | 900 | 3.21% |
Dec 31, 2005 | 28,000 | 12,700 | 83.01% |
Dec 31, 2004 | 15,300 | 1,500 | 10.87% |
Dec 31, 2003 | 13,800 | 800 | 6.15% |
Dec 31, 2002 | 13,000 | 300 | 2.36% |
Dec 31, 2001 | 12,700 | 500 | 4.10% |
Dec 31, 2000 | 12,200 | -100 | -0.81% |
Dec 31, 1999 | 12,300 | 0 | - |
Dec 31, 1998 | 12,300 | 3,470 | 39.30% |
Dec 31, 1997 | 8,830 | 5,705 | 182.56% |
Dec 31, 1996 | 3,125 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
DVA News
- 14 days ago - 20 stocks primed for rapid growth while trading at half of Nvidia's valuation - Market Watch
- 17 days ago - DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates - PRNewsWire
- 20 days ago - DaVita: International Expansion And Buybacks Will Boost Returns - Seeking Alpha
- 27 days ago - DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering - PRNewsWire
- 27 days ago - DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship - PRNewsWire
- 27 days ago - DaVita Inc. Announces Offering of $750 Million Senior Notes - PRNewsWire
- 5 weeks ago - DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - DaVita beats quarterly profit estimates amid stable demand for dialysis services - Reuters